CN104557939B - 吡咯并吡嗪化合物的盐酸盐及其应用 - Google Patents

吡咯并吡嗪化合物的盐酸盐及其应用 Download PDF

Info

Publication number
CN104557939B
CN104557939B CN201410567613.3A CN201410567613A CN104557939B CN 104557939 B CN104557939 B CN 104557939B CN 201410567613 A CN201410567613 A CN 201410567613A CN 104557939 B CN104557939 B CN 104557939B
Authority
CN
China
Prior art keywords
methyl
alkyl
compound
formula
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410567613.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104557939A (zh
Inventor
王勇
赵立文
谢同
沙向阳
苏小川
张波
叶嘉伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Shenghe pharmaceutical research and Development Co., Ltd
Original Assignee
Nanjing Sanhome Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd
Priority to CN201410567613.3A priority Critical patent/CN104557939B/zh
Publication of CN104557939A publication Critical patent/CN104557939A/zh
Application granted granted Critical
Publication of CN104557939B publication Critical patent/CN104557939B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
CN201410567613.3A 2013-10-23 2014-10-22 吡咯并吡嗪化合物的盐酸盐及其应用 Active CN104557939B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410567613.3A CN104557939B (zh) 2013-10-23 2014-10-22 吡咯并吡嗪化合物的盐酸盐及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310503651 2013-10-23
CN2013105036518 2013-10-23
CN201410567613.3A CN104557939B (zh) 2013-10-23 2014-10-22 吡咯并吡嗪化合物的盐酸盐及其应用

Publications (2)

Publication Number Publication Date
CN104557939A CN104557939A (zh) 2015-04-29
CN104557939B true CN104557939B (zh) 2018-10-23

Family

ID=52992264

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410568697.2A Active CN104557940B (zh) 2013-10-23 2014-10-22 Bcr-abl激酶抑制剂及其应用
CN201410567613.3A Active CN104557939B (zh) 2013-10-23 2014-10-22 吡咯并吡嗪化合物的盐酸盐及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410568697.2A Active CN104557940B (zh) 2013-10-23 2014-10-22 Bcr-abl激酶抑制剂及其应用

Country Status (3)

Country Link
CN (2) CN104557940B (fr)
TW (1) TWI523856B (fr)
WO (1) WO2015058661A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632347B (zh) * 2015-10-28 2021-09-10 南京圣和药物研发有限公司 一种吡咯并吡嗪化合物及其盐的制备方法
CN106632343A (zh) * 2015-10-28 2017-05-10 南京圣和药业股份有限公司 吡咯并吡嗪化合物i晶型及其制备方法
CN106632146A (zh) * 2015-10-28 2017-05-10 南京圣和药业股份有限公司 一种二炔基化合物及其合成方法
CN106632346A (zh) * 2015-10-28 2017-05-10 南京圣和药业股份有限公司 吡咯并吡嗪化合物的新晶型及其制备方法
CN106632345A (zh) * 2015-10-28 2017-05-10 南京圣和药业股份有限公司 吡咯并吡嗪化合物a晶型及其制备方法
CN106632344A (zh) * 2015-10-28 2017-05-10 南京圣和药业股份有限公司 吡咯并吡嗪化合物的晶型及其制备方法
CN108473476B (zh) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775411A (zh) * 2012-08-17 2012-11-14 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的芳乙炔基苯甲酰胺类化合物
CN103664787A (zh) * 2012-09-17 2014-03-26 南京圣和药业有限公司 炔杂芳环化合物及其应用
CN103848829A (zh) * 2012-11-28 2014-06-11 南京圣和药业有限公司 杂芳基炔烃化合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775411A (zh) * 2012-08-17 2012-11-14 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的芳乙炔基苯甲酰胺类化合物
CN103664787A (zh) * 2012-09-17 2014-03-26 南京圣和药业有限公司 炔杂芳环化合物及其应用
CN103848829A (zh) * 2012-11-28 2014-06-11 南京圣和药业有限公司 杂芳基炔烃化合物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib;Xiaomei Ren 等;《Journal of Medicinal Chemistry》;20130109;第56卷(第3期);第879-894页，参见摘要，第879页，Figure 1-2、5-7，Scheme 1-2，Table 1，第886页最后一段至第887页，第889页左栏第3-4段，右栏最后一段，第890页左栏最后一段至右栏第2段 *
Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform;Bimbisar Desai 等;《Journal of Medicinal Chemistry》;20130226;第56卷(第7期);第3033-3047页，尤其第3035页左栏至右栏第1段，Figure 4、12-15，Table 1-2，摘要 *

Also Published As

Publication number Publication date
CN104557940A (zh) 2015-04-29
TW201516048A (zh) 2015-05-01
CN104557939A (zh) 2015-04-29
TWI523856B (zh) 2016-03-01
CN104557940B (zh) 2018-10-02
WO2015058661A1 (fr) 2015-04-30

Similar Documents

Publication Publication Date Title
CN104557939B (zh) 吡咯并吡嗪化合物的盐酸盐及其应用
CN104797581B (zh) 杂芳基炔烃化合物及其应用
EP3392245A1 (fr) Nouveau double inhibiteur de egfr et de alk
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
CN101503407B (zh) 一种咪唑并吡啶类化合物
CN102503959B (zh) 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN105461694B (zh) 取代的杂芳基化合物及其组合物和用途
EP3312180B1 (fr) Utilisation de dérivés de ptéridinone en tant qu'inhibiteur de l'egfr
CN105777756A (zh) 杂芳化合物及其在药物中的应用
CN112010828B (zh) Cdk7小分子抑制剂的化合物及其应用
EP3929195A1 (fr) Nouveau dérivé de pyrido[3,4-d]pyrimidin-8-one ayant une activité inhibitrice de protéine kinase, et composition pharmaceutique pour prévenir, soulager ou traiter le cancer, comprenant celui-ci
JP2023504230A (ja) Ｐｒｍｔ５阻害剤の組合せ医薬
EP4105213A1 (fr) Dérivé de pyrido[3,4-d]pyrimidine et composition pharmaceutique thérapeutique le comprenant
CN108570048A (zh) 取代的杂芳基化合物及其组合物和用途
EP2900667B1 (fr) Moyens et procédé pour traiter des tumeurs solides
CN106478607A (zh) 取代的杂芳基化合物及其组合物和用途
CN108084177A (zh) 一种小檗碱9-位吡唑衍生物及其制备和应用
CN105924444B (zh) Jak抑制剂的晶型及其制备方法
CN110407854A (zh) 新的四环化合物
WO2019001307A1 (fr) Composé amide, composition le contenant, et utilisation associée
CN111138459B (zh) Fgfr4抑制剂的光学异构体及其应用
US20150353524A1 (en) Pyridine compounds used as pi3 kinase inhibitors
CN109438279B (zh) 一种克服egfr耐药突变的小分子化合物及其制备方法和用途
CN102617478A (zh) 苯并咪唑、噁唑和噻唑衍生物的合成及其应用
US20180244695A1 (en) Quinoline derivative, and pharmaceutical composition, preparation method and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200330

Address after: No.99 Yunliang Hexi Road, Qilin science and Technology Innovation Park, Jiangning District, Nanjing City, Jiangsu Province

Patentee after: Nanjing Shenghe pharmaceutical research and Development Co., Ltd

Address before: 210038 No. 9 Zhong Hui Road, Nanjing economic and Technological Development Zone, Jiangsu

Patentee before: NANJING SANHOME PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right